MANGALAM DRUGS AND ORGANICS
|
MANGALAM DRUGS AND ORGANICS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -5.72 | 0.80 | 12.42 | 17.67 | 5.21 |
| CEPS(Rs) | 3.53 | 7.74 | 18.89 | 23.47 | 10.41 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 89.93 | 96.00 | 95.12 | 82.63 | 65.67 |
| Tax Rate(%) | 18.16 | 42.63 | 29.12 | 29.22 | -32.00 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 4.72 | 6.91 | 10.88 | 15.08 | 7.57 |
| EBIT Margin(%) | 0.78 | 4.08 | 8.62 | 12.70 | 5.32 |
| Pre Tax Margin(%) | -3.00 | 0.59 | 6.15 | 10.27 | 2.00 |
| PAT Margin (%) | -2.45 | 0.34 | 4.36 | 7.27 | 2.64 |
| Cash Profit Margin (%) | 1.51 | 3.29 | 6.63 | 9.66 | 5.26 |
| Performance Ratios | |||||
| ROA(%) | -2.53 | 0.37 | 6.64 | 11.31 | 3.73 |
| ROE(%) | -6.15 | 0.84 | 13.97 | 23.83 | 8.27 |
| ROCE(%) | 1.23 | 6.65 | 18.34 | 28.01 | 10.66 |
| Asset Turnover(x) | 1.03 | 1.08 | 1.52 | 1.56 | 1.42 |
| Sales/Fixed Asset(x) | 1.47 | 1.60 | 2.15 | 2.09 | 1.86 |
| Working Capital/Sales(x) | 19.58 | 9.41 | 8.21 | 15.49 | 32.26 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.68 | 0.62 | 0.47 | 0.48 | 0.54 |
| Receivable days | 36.88 | 45.61 | 40.78 | 44.73 | 33.58 |
| Inventory Days | 129.28 | 124.81 | 71.08 | 58.56 | 80.60 |
| Payable days | 133.22 | 109.29 | 58.29 | 72.42 | 83.15 |
| Valuation Parameters | |||||
| PER(x) | - | 121.95 | 8.28 | 5.62 | 5.82 |
| PCE(x) | 26.27 | 12.63 | 5.44 | 4.24 | 2.92 |
| Price/Book(x) | 1.03 | 1.02 | 1.08 | 1.20 | 0.46 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.65 | 0.61 | 0.53 | 0.57 | 0.34 |
| EV/Core EBITDA(x) | 13.76 | 8.73 | 4.88 | 3.80 | 3.88 |
| EV/EBIT(x) | 84.19 | 15.06 | 6.16 | 4.52 | 5.79 |
| EV/CE(x) | 1.01 | 1.01 | 0.73 | 0.84 | 0.42 |
| M Cap / Sales | 0.40 | 0.42 | 0.36 | 0.41 | 0.17 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -0.98 | -17.47 | 17.25 | 36.25 | 24.07 |
| Core EBITDA Growth(%) | -33.13 | -46.77 | -15.30 | 133.25 | 148.80 |
| EBIT Growth(%) | -81.15 | -61.00 | -20.37 | 193.25 | 472.52 |
| PAT Growth(%) | -812.51 | -93.54 | -29.72 | 238.94 | 202.76 |
| EPS Growth(%) | -812.48 | -93.54 | -29.72 | 238.94 | 202.76 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.67 | 0.49 | 0.52 | 0.49 | 0.48 |
| Current Ratio(x) | 1.10 | 1.24 | 1.42 | 1.23 | 1.09 |
| Quick Ratio(x) | 0.42 | 0.40 | 0.52 | 0.69 | 0.50 |
| Interest Cover(x) | 0.21 | 1.17 | 3.48 | 5.24 | 1.60 |
| Total Debt/Mcap(x) | 0.65 | 0.48 | 0.48 | 0.41 | 1.04 |
Compare Financial Ratios of peers of MANGALAM DRUGS AND ORGANICS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANGALAM DRUGS AND ORGANICS | ₹161.1 Cr | -11% | -13.4% | 3.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,936.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹152,157.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
| CIPLA | ₹116,200.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,325.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,037.4 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics | |
MANGALAM DRUGS AND ORGANICS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANGALAM DRUGS AND ORGANICS | -11% |
-13.4% |
3.6% |
| SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses
